{"log_id": 7435316455430942814, "direction": 0, "words_result_num": 27, "words_result": [{"probability": {"variance": 0, "average": 0.852187, "min": 0.852187}, "location": {"width": 23, "top": 11, "height": 24, "left": 1153}, "words": "同"}, {"probability": {"variance": 0.000216, "average": 0.994253, "min": 0.916876}, "location": {"width": 853, "top": 143, "height": 58, "left": 160}, "words": "介于安慰剂与25mg之间。对于ACR标准中所有指标以及ACR中没有涉及的其他RA"}, {"probability": {"variance": 0, "average": 0.999054, "min": 0.999054}, "location": {"width": 28, "top": 147, "height": 29, "left": 1164}, "words": "国"}, {"probability": {"variance": 1.1e-05, "average": 0.997971, "min": 0.984023}, "location": {"width": 854, "top": 192, "height": 58, "left": 161}, "words": "指标,如晨僵,依那西普都明显优于安慰剂。试验中每三个月要进行一次健康评价问卷"}, {"probability": {"variance": 5.2e-05, "average": 0.997863, "min": 0.954945}, "location": {"width": 839, "top": 243, "height": 56, "left": 178}, "words": "HAQ),对包括残疾、生活力、精神健康状态、一般健康状态以及关节炎相关的健康"}, {"probability": {"variance": 0.000281, "average": 0.994435, "min": 0.90669}, "location": {"width": 856, "top": 293, "height": 57, "left": 162}, "words": "状况子项进行评价。与安慰剂组相比,依那西普治疗的患者在第3个月和6个月时,HAQ"}, {"probability": {"variance": 1.2e-05, "average": 0.998091, "min": 0.987922}, "location": {"width": 231, "top": 363, "height": 36, "left": 161}, "words": "的所有亚项均有所改善"}, {"probability": {"variance": 1.3e-05, "average": 0.998225, "min": 0.983092}, "location": {"width": 814, "top": 393, "height": 54, "left": 207}, "words": "依那西普停药后,关节炎症状一般在一个月内再次出现。停药达24个月后再次使"}, {"probability": {"variance": 4.9e-05, "average": 0.998096, "min": 0.95608}, "location": {"width": 859, "top": 442, "height": 56, "left": 162}, "words": "用依那西普治疗,根据开放性研究结果,这些患者能和未中断用药的患者取得一致的临"}, {"probability": {"variance": 1e-05, "average": 0.998493, "min": 0.986292}, "location": {"width": 858, "top": 491, "height": 57, "left": 162}, "words": "床疗效。在48个月开放性连续治疗研究中观察到了依那西普的连续效应。目前尚无更"}, {"probability": {"variance": 2.2e-05, "average": 0.997525, "min": 0.983719}, "location": {"width": 231, "top": 560, "height": 36, "left": 161}, "words": "长时间连续用药的经验"}, {"probability": {"variance": 3.8e-05, "average": 0.997715, "min": 0.962973}, "location": {"width": 816, "top": 590, "height": 55, "left": 207}, "words": "在一项随机、活性药对照的研究中对依那西普与甲氨蝶呤有效性进行了比较,该试"}, {"probability": {"variance": 0.000162, "average": 0.995904, "min": 0.924879}, "location": {"width": 860, "top": 640, "height": 56, "left": 162}, "words": "验以盲性放射相评价作为主要终点,在632位从未接受过甲氨蝶呤治疗的活动性类风湿"}, {"probability": {"variance": 0.00571, "average": 0.985167, "min": 0.508173}, "location": {"width": 865, "top": 689, "height": 55, "left": 161}, "words": "关节炎成人患者中(病程<3年)进行。连续24个月每周两次皮下注射10mg或25mg"}, {"probability": {"variance": 0.000201, "average": 0.994954, "min": 0.913633}, "location": {"width": 863, "top": 737, "height": 56, "left": 165}, "words": "的依那西普,甲氨蝶呤的剂量在试验的前8周从每周7.5mg逐渐增加到每周20mg,并"}, {"probability": {"variance": 0.006144, "average": 0.983061, "min": 0.503196}, "location": {"width": 866, "top": 785, "height": 57, "left": 164}, "words": "持续到24个月。25mg依那西普组在治疗2周内包括活动性发作在内的临床改善效果与"}, {"probability": {"variance": 0.000111, "average": 0.996178, "min": 0.938154}, "location": {"width": 867, "top": 834, "height": 58, "left": 165}, "words": "先前进行的试验相同,并持续到24个月。在用药前患者中度失能,平均HAQ值为14"}, {"probability": {"variance": 0.001498, "average": 0.989405, "min": 0.762147}, "location": {"width": 866, "top": 883, "height": 58, "left": 165}, "words": "到1.5。25mg依那西普治疗12个月后获得实质性改善,约44%的患者HAQ达到正常"}, {"probability": {"variance": 6.9e-05, "average": 0.997154, "min": 0.958309}, "location": {"width": 505, "top": 943, "height": 45, "left": 166}, "words": "值(小于0.5)。这个效果可以维持到研究的第二年"}, {"probability": {"variance": 0.000993, "average": 0.989473, "min": 0.844244}, "location": {"width": 822, "top": 981, "height": 55, "left": 211}, "words": "在此研究中,关节结构性损伤采用放射相评价,以 Sharp总分(TSS)及组成部分"}, {"probability": {"variance": 0.000511, "average": 0.992258, "min": 0.871626}, "location": {"width": 865, "top": 1029, "height": 57, "left": 168}, "words": "即侵蚀评分、关节间隙狭窄(JSN)评分的变化表示。获得手腕和脚部在基线、第6个"}, {"probability": {"variance": 5.3e-05, "average": 0.997092, "min": 0.956719}, "location": {"width": 868, "top": 1077, "height": 57, "left": 168}, "words": "月、12个月、24个月的放射学图像。10mg依那西普对关节结构性损伤的效果始终低于"}, {"probability": {"variance": 0.002403, "average": 0.987941, "min": 0.684906}, "location": {"width": 857, "top": 1126, "height": 60, "left": 168}, "words": "25mg的依那西普。25mg依那西普在12个月和24个月的侵蚀评分都明显忧于甲氨蝶呤"}, {"probability": {"variance": 0.001648, "average": 0.991895, "min": 0.745428}, "location": {"width": 808, "top": 1175, "height": 57, "left": 170}, "words": "甲氨蝶呤和25mg依那西普的TSS和JSN得分无显著的统计学差异。结果见下图"}, {"probability": {"variance": 0.000268, "average": 0.994084, "min": 0.907722}, "location": {"width": 675, "top": 1272, "height": 54, "left": 290}, "words": "放射相变化:RA患者(病程<3年)中依那西普与甲氨蝶呤的比较"}, {"probability": {"variance": 0.000208, "average": 0.992736, "min": 0.954802}, "location": {"width": 178, "top": 1617, "height": 34, "left": 785}, "words": "第16页共31页"}, {"probability": {"variance": 4e-05, "average": 0.995788, "min": 0.976254}, "location": {"width": 164, "top": 1641, "height": 25, "left": 174}, "words": "版本号:20090118"}], "language": 3}